One of the largest bronchodilator manufacturers in Russia has opened in the Irkutsk region. The launch of the large-scale project for the development and production of bronchodilators at JSC "Djinatex" was initiated by the Russian pharmaceutical company AO "Farmasintez."
The production of the first batch of drugs for treating chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma, is planned for the near future.
According to Olga Daniushkina, CEO of LLC "Djinatex," the company has already developed and registered its first original drug, with subsequent ones currently in active development and set to enter the market soon. By the end of the decade, the company plans to produce around thirty different medications.
"Our goal is to become one of the leading domestic manufacturers of high-quality, effective, and affordable medications for treating respiratory system diseases, ensuring a market share of over 25% of bronchodilators in Russia in the medium term," emphasized the company's leader.
The manufacturer has established a full production cycle, including the creation of finished drug formulations, at its plant in Irkutsk. Over a hundred jobs have been created as part of this initiative.
The products from LLC "Djinatex" are expected to significantly increase the accessibility of modern, high-quality therapy for patients suffering from respiratory conditions, reduce state expenses on purchasing costly foreign equivalents, and contribute to improving the health of the nation. Respiratory diseases remain one of the key medical challenges of our time. According to the WHO, COPD is among the top six causes of death worldwide.
Russia faces a high prevalence of COPD and severe bronchial asthma, resulting in significant economic losses for the state, amounting to hundreds of billions of rubles annually. LLC "Djinatex" aims to change this situation by providing affordable, high-quality domestic medications that match the efficacy and safety of foreign counterparts.
"We are currently the only enterprise in Siberia producing drugs for treating asthma and COPD. The number of patients has sharply increased after the COVID-19 pandemic, so we've focused on this sector to support the population of our country. There is a lot of work ahead, and we are fully prepared for it," stated Olga Daniushkina.
Source: Kommersant
